Funded Biotechnology Startups in Calgary
Among the 10 most recent biotechnology rounds shown, the largest disclosed amount is Oncolytics Biotech’s $20M (2025-04-10), and it stands well above the n…
Among the 10 most recent biotechnology rounds shown, the largest disclosed amount is Oncolytics Biotech’s $20M (2025-04-10), and it stands well above the next-highest disclosed rounds such as FluroTech’s $16M (2024-05-01) and Xortx Therapeutics’s $5M (2026-05-14). Most other disclosed amounts cluster between $150K and $6M, with Marvel Biosciences at $360K (2026-04-08), Resverlogix at $2M (2026-05-19), and Psygen Labs at $6M (2021-08-05).
The geography is heavily Calgary-centered: 8 of 10 entries list Calgary, Alberta (with one additional Ontario entry, Zamplo in 2025-01-03). Temporally, rounds span 2021-08-05 (Psygen Labs, $6M) through the most recent 2026-05-19 (Resverlogix, $2M). Stage/disclosure is also concentrated: 5 of 10 rounds are “Series Unknown,” and 3 of 10 amounts are “undisclosed” (NanoTess Inc., 2026-04-27; Syantra, 2025-02-26; Qualisure Diagnostics, 2022-09-13).
Most recent rounds
10 shownRelated listings
Frequently asked
Which disclosed round is the size outlier, and how does it compare to the next-largest disclosed amount?
Oncolytics Biotech’s disclosed $20M on 2025-04-10 is the clearest outlier; the next-largest disclosed entries are FluroTech at $16M (2024-05-01) and then Xortx Therapeutics at $5M (2026-05-14).
Do the most recent rounds cluster in a narrow time window?
Yes. Five of the 10 rows fall in 2026: Resverlogix ($2M, 2026-05-19), Xortx Therapeutics ($5M, 2026-05-14), NanoTess Inc. (undisclosed, 2026-04-27), and Marvel Biosciences ($360K, 2026-04-08), plus the next earlier 2025-04-10 gap to Oncolytics Biotech ($20M).
Is Calgary over-represented versus other geographies in this list?
Calgary dominates: 8 of 10 entries list Calgary, Alberta (including Resverlogix on 2026-05-19 through Qualisure Diagnostics in 2022-09-13). The only other geography shown is Zamplo in Calgary, Ontario (seed, $150K on 2025-01-03).
What does the stage/disclosure mix look like among these recent biotechnology rounds?
“Series Unknown” appears in 5 of 10 rows (e.g., Resverlogix on 2026-05-19 and FluroTech on 2024-05-01). Separately, 3 of 10 amounts are undisclosed (NanoTess Inc., 2026-04-27; Syantra, 2025-02-26; Qualisure Diagnostics, 2022-09-13).
Which entries are potential follow-up candidates because their disclosed amounts sit at the low end?
Several are clustered near sub-$1M levels: Marvel Biosciences at $360K (2026-04-08) and Zamplo at $150K (2025-01-03). Others are still low but higher, like Resverlogix at $2M (2026-05-19) versus the larger disclosed $6M–$20M rounds (Psygen Labs $6M in 2021-08-05; FluroTech $16M in 2024-05-01; Oncolytics Biotech $20M in 2025-04-10).
If a reviewer wants to understand stage variety, where are the clearly specified stages in this set?
Beyond “Series Unknown,” the explicitly shown stages include Seed (Zamplo: $150K on 2025-01-03; Qualisure Diagnostics: undisclosed on 2022-09-13) and Debt Financing (Psygen Labs: $6M on 2021-08-05). These specified-stage entries are fewer than the “Series Unknown” rows (2 vs. 5).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.